Engineering of stable bispecific antibodies targeting IL-17A and IL-23

Robert Mabry1,6, Katherine E. Lewis2, Margaret Moore3, Patricia A. McKernan1, Thomas R. Bukowski3, Kristen Bontadelli2, Ty Brender1, Shannon Okada2, Karen Lum3, James West3, Joseph L. Kuijper1, Dan Ardourel1, Secil Franke1, Luann Lockwood1, Tuyen Vu1, Amanda Frank1, Mark W. Appleby1, Anitra Wolf3, Brian Reardon3, Nels B. Hamacher3, Brenda Stevens3, Patsy Lewis3, Kenneth B. Lewis3, Debra G. Gilbertson1, Megan Lantry3, Susan H. Julien3, Craig Ostrander3, Chung Chan3, Kelly Byrnes-Blake4, Jennifer Brody5, Scott Presnell5, Brent Meengs3, Steven D. Levin2 and Mark Snavely1 Molecular Biology and Protein Engineering, Immunology, Protein Science, Pre-clinical Development and Scientific Computing, ZymoGenetics, Inc., 1201 Eastlake Ave. E, Seattle, WA 98102, USA